Mark Mayeda, MD
Radiation Oncology · Honolulu, HINPI 1295181493
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 26.8% of the total. 2025 is the largest year on record at $1,075, more than ten times the $14 reported in 2021.
Across 85 payments — averaging $27.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$630
- Novartis$315
- Fujifilm Healthcare Americas Corporation$205
- Regeneron Healthcare Solutions, Inc.$155
- Coherus Oncology, Inc.$125
- Johnson & Johnson$113
- plus $812 from 16 others
What the payments were for
- Food & beverage$2,355100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $630 |
| Novartis | 16 | $315 |
| Fujifilm Healthcare Americas Corporation | 3 | $205 |
| Regeneron Healthcare Solutions, Inc. | 2 | $155 |
| Coherus Oncology, Inc. | 5 | $125 |
| Johnson & Johnson | 4 | $113 |
| Pfizer | 5 | $100 |
| Eisai Inc. | 4 | $95 |
| Astellas Pharma US Inc | 4 | $93 |
| E.r. Squibb & Sons, L.L.C. | 4 | $76 |
| Sumitomo Pharma America, Inc. | 4 | $60 |
| Merck | 3 | $55 |
| Teleflex LLC | 2 | $51 |
| Incyte Corporation | 2 | $50 |
| Novocure Inc. | 2 | $43 |
| Tempus AI, Inc | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 1 | $36 |
| Agios Pharmaceuticals, Inc. | 1 | $31 |
| Exelixis Inc. | 1 | $26 |
| Karyopharm Therapeutics Inc. | 1 | $26 |
| Boehringer Ingelheim | 1 | $18 |
| Monteris Medical Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,355 in reported general payments places this provider in the 75th percentile of 27 radiation oncology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 21 | $484 |
| Lorazepam | 11 | $6 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Honolulu
- Laeton PangHonolulu$10K
- Michael RoachHonolulu$9K
- Jared HaraHonolulu$3K
- Anthony MichaudHonolulu$3K
- John LedererHonolulu$3K
- Christina SpeirsHonolulu$2K
- Samuel BirerHonolulu$2K
- Richard LeeHonolulu$2K
- Scott MoonHonolulu$2K
- Susie ChenHonolulu$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.